Real-world use of an MS blood test shows how it helps monitor disease activity and guide treatment decisions in U.S. patients ...

A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

A new MS blood test from Roche has received EU approval and may help track disease activity by measuring nerve damage linked ...

The test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

Roche has received CE mark approval of its Elecsys neurofilament light chain (NfL) test, which is designed to detect ...

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing ...

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...

Scientists have found blood protein signals that may flag multiple sclerosis up to seven years before symptoms begin. Spotting early warning signs means more opportunities to treat or prevent multiple ...

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables grea ...